Cargando…

Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life

Background. Depression and anxiety disorders are major world-wide problems. There are no or few epidemiological studies investigating the prevalence of depression, generalized anxiety disorder and anxiety disorders in general in the Swedish population. Methods. Data were obtained by means of a posta...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Robert, Carlbring, Per, Heedman, Åsa, Paxling, Björn, Andersson, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709104/
https://www.ncbi.nlm.nih.gov/pubmed/23862109
http://dx.doi.org/10.7717/peerj.98
_version_ 1782276707016769536
author Johansson, Robert
Carlbring, Per
Heedman, Åsa
Paxling, Björn
Andersson, Gerhard
author_facet Johansson, Robert
Carlbring, Per
Heedman, Åsa
Paxling, Björn
Andersson, Gerhard
author_sort Johansson, Robert
collection PubMed
description Background. Depression and anxiety disorders are major world-wide problems. There are no or few epidemiological studies investigating the prevalence of depression, generalized anxiety disorder and anxiety disorders in general in the Swedish population. Methods. Data were obtained by means of a postal survey administered to 3001 randomly selected adults. After two reminders response rate was 44.3%. Measures of depression and general anxiety were the 9-item Patient Health Questionnaire Depression Scale (PHQ-9) and the 7-item Generalized Anxiety Disorder Scale (GAD-7). The PHQ-9 identified participants who had experienced clinically significant depression (PHQ-9 ≥ 10), and who had a diagnosis of major depression (defined by using a PHQ-9 scoring algorithm). Clinically significant anxiety was defined as having a GAD-7 score ≥ 8. To specifically measure generalized anxiety disorder, the Generalized Anxiety Disorder Questionnaire-IV (GAD-Q-IV) was used with an established cut-off. Health-related quality of life was measured using the EuroQol (EQ-5D). Experiences of treatments for psychiatric disorders were also assessed. Results. Around 17.2% (95% CI: 15.1–19.4) of the participants were experiencing clinically significant depression (10.8%; 95% CI: 9.1–12.5) and clinically significant anxiety (14.7%; 95% CI: 12.7–16.6). Among participants with either clinically significant depression or anxiety, nearly 50% had comorbid disorders. The point prevalence of major depression was 5.2% (95% CI: 4.0–6.5), and 8.8% (95% CI: 7.3–10.4) had GAD. Among those with either of these disorders, 28.2% had comorbid depression and GAD. There were, generally, significant gender differences, with more women having a disorder compared to men. Among those with depression or anxiety, only between half and two thirds had any treatment experience. Comorbidity was associated with higher symptom severity and lower health-related quality of life. Conclusions. Epidemiological data from the Swedish community collected in this study provide point prevalence rates of depression, anxiety disorders and their comorbidity. These conditions were shown in this study to be undertreated and associated with lower quality of life, that need further efforts regarding preventive and treatment interventions.
format Online
Article
Text
id pubmed-3709104
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-37091042013-07-16 Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life Johansson, Robert Carlbring, Per Heedman, Åsa Paxling, Björn Andersson, Gerhard PeerJ Epidemiology Background. Depression and anxiety disorders are major world-wide problems. There are no or few epidemiological studies investigating the prevalence of depression, generalized anxiety disorder and anxiety disorders in general in the Swedish population. Methods. Data were obtained by means of a postal survey administered to 3001 randomly selected adults. After two reminders response rate was 44.3%. Measures of depression and general anxiety were the 9-item Patient Health Questionnaire Depression Scale (PHQ-9) and the 7-item Generalized Anxiety Disorder Scale (GAD-7). The PHQ-9 identified participants who had experienced clinically significant depression (PHQ-9 ≥ 10), and who had a diagnosis of major depression (defined by using a PHQ-9 scoring algorithm). Clinically significant anxiety was defined as having a GAD-7 score ≥ 8. To specifically measure generalized anxiety disorder, the Generalized Anxiety Disorder Questionnaire-IV (GAD-Q-IV) was used with an established cut-off. Health-related quality of life was measured using the EuroQol (EQ-5D). Experiences of treatments for psychiatric disorders were also assessed. Results. Around 17.2% (95% CI: 15.1–19.4) of the participants were experiencing clinically significant depression (10.8%; 95% CI: 9.1–12.5) and clinically significant anxiety (14.7%; 95% CI: 12.7–16.6). Among participants with either clinically significant depression or anxiety, nearly 50% had comorbid disorders. The point prevalence of major depression was 5.2% (95% CI: 4.0–6.5), and 8.8% (95% CI: 7.3–10.4) had GAD. Among those with either of these disorders, 28.2% had comorbid depression and GAD. There were, generally, significant gender differences, with more women having a disorder compared to men. Among those with depression or anxiety, only between half and two thirds had any treatment experience. Comorbidity was associated with higher symptom severity and lower health-related quality of life. Conclusions. Epidemiological data from the Swedish community collected in this study provide point prevalence rates of depression, anxiety disorders and their comorbidity. These conditions were shown in this study to be undertreated and associated with lower quality of life, that need further efforts regarding preventive and treatment interventions. PeerJ Inc. 2013-07-09 /pmc/articles/PMC3709104/ /pubmed/23862109 http://dx.doi.org/10.7717/peerj.98 Text en © 2013 Johansson et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Epidemiology
Johansson, Robert
Carlbring, Per
Heedman, Åsa
Paxling, Björn
Andersson, Gerhard
Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life
title Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life
title_full Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life
title_fullStr Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life
title_full_unstemmed Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life
title_short Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life
title_sort depression, anxiety and their comorbidity in the swedish general population: point prevalence and the effect on health-related quality of life
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709104/
https://www.ncbi.nlm.nih.gov/pubmed/23862109
http://dx.doi.org/10.7717/peerj.98
work_keys_str_mv AT johanssonrobert depressionanxietyandtheircomorbidityintheswedishgeneralpopulationpointprevalenceandtheeffectonhealthrelatedqualityoflife
AT carlbringper depressionanxietyandtheircomorbidityintheswedishgeneralpopulationpointprevalenceandtheeffectonhealthrelatedqualityoflife
AT heedmanasa depressionanxietyandtheircomorbidityintheswedishgeneralpopulationpointprevalenceandtheeffectonhealthrelatedqualityoflife
AT paxlingbjorn depressionanxietyandtheircomorbidityintheswedishgeneralpopulationpointprevalenceandtheeffectonhealthrelatedqualityoflife
AT anderssongerhard depressionanxietyandtheircomorbidityintheswedishgeneralpopulationpointprevalenceandtheeffectonhealthrelatedqualityoflife